Introduction
Oncogenic viruses have been implicated in approximately 15% of all human cancers (reviewed in zur Hausen, 1991) . In cervical cancer, an intimate association with infection by certain types of human papillomaviruses (HPVs) has been established. HPVs are a large group of epitheliotropic viruses with currently more than 100 genotypes. Some HPVs specifically infect the mucosa of the human anogenital tract. Based on the pathology of the lesions they cause, these HPV types are subdivided into 'low-risk' HPVs, which cause benign tumors (condyloma acuminata, 'genital warts'), and 'high-risk' HPVs, which cause squamous epithelial lesions that have a certain potential to undergo malignant transformation. Once a lesion has progressed from the premalignant state to overt cancer, only a small portion of the HPV genome is retained and expressed in neoplastic cells (reviewed in Howley and Lowy, 2001; Munger, 2002; zur Hausen, 1996) . The epidemiological and molecular evidence is sufficient to conclude that high-risk HPVs such as HPV-16 and HPV-18 are the etiological agents for cervical cancer (World Health Organisation, 1995) . However, carcinogenic progression of high-risk HPV associated lesions is generally a rare event with a long latency period suggesting that additional cellular mutations may also be necessary for progression to cancer. Genomic instability critically contributes to cervical carcinogenesis by increasing the incidence of cellular mutations (reviewed in zur Hausen, 1991) . In this review, we will summarize the current model how high-risk HPVs can re-program the cellular DNA synthesis machinery of the infected host cell to ensure virus reproduction. We will show that by doing so, high-risk HPVs also subvert mitotic fidelity of the host cell by inducing centrosome duplication errors. We will finally discuss how these events set the stage for chromosomal instability and carcinogenic progression.
Human papillomaviruses and cancer
HPVs are small DNA tumor viruses with a genome size of approximately 8000 base pairs. Only one strand of the double-stranded circular genomes is transcribed and encodes approximately 10 open reading frames. The HPV genome can be divided into three regions: a non coding 'long control region' (LCR), which contains DNA elements that are involved in the regulation of viral transcription and replication, and coding regions for the early (E) and late (L) genes. Early genes encode proteins that are necessary for viral genome replication. The E1 gene encodes a DNA helicase that interacts with the E2 protein to bind to the viral origin of replication in the LCR. E2 also functions as transcriptional regulator that binds to specific sequences in the LCR and negatively regulates expression of viral genes. E6 and E7 encode proteins that interact with the p53 and retinoblastoma (pRB) tumor suppressors, respectively, to establish and/or maintain a cellular milieu that allows for viral genome replication. The biological functions and molecular targets of the HPV E4 and E5 proteins are less well defined, but they too contribute to the viral life cycle. The two late genes L1 and L2 encode the major and minor viral capsid proteins, respectively (reviewed in Howley and Lowy, 2001) .
It is believed that high-risk HPVs gain access to epithelial cells through small injuries or at the squamocolumnar transformation zone of the cervix where basal-like cells are particularly readily accessible. The virus is taken up by a receptor-mediated mechanism, decapsidated and the viral genome is transported to the nucleus. The molecular details of these processes are still largely unknown. The HPV genome is initially replicated and maintained as episomal DNA at approximately 50 copies in the basal cells of the infected host epithelium. Like other small DNA tumor viruses, HPVs do not encode all the proteins necessary for their replication and need to usurp the replication machinery of the host cell. However, the productive phase of the viral life cycle occurs in the suprabasal epithelial layers where the host keratinocytes undergo terminal differentiation and have permanently exited the proliferative stage. High copy amplification of viral DNA, late gene expression and production of infectious particles can only occur in differentiated cells (reviewed in Howley and Lowy, 2001; Lowy and Howley, 2001; Munger, 2002) . Here, the E6 and E7 oncoproteins exert their physiological functions to reprogram the cell cycle machinery of the host cell in order to create a replication competent milieu. To accomplish this function, high risk HPV E6 and E7 interact with critical regulators of the host cell cycle machinery (Figure 1 ). The HPV E7 oncoprotein binds and degrades the retinoblastoma tumor suppressor (pRB) (Boyer et al., 1996; Dyson et al., 1989) and inactivates the cyclin-dependent kinase (cdk) inhibitors p21 waf1/cip1 (Funk et al., 1997; Jones et al., 1997) and p27 kip1 (Zerfass-Thome et al., 1996) . As a consequence, E2F transcription factors, which are normally active as repressors due to their association with pRB, are aberrantly stimulated and activate expression of genes necessary for entry and transit through S phase. Cyclin E and cyclin A (Martin et al., 1998; Schulze et al., 1998) , as well as the phosphatase cdc25 (Katich et al., 2001) , which are important positive regulators of cdk2 activity, are atypically expressed in high-risk HPV E7 expressing cells, resulting in abnormal patterns of cdk2 activity (Zerfass et al., 1995) . HPV E7 has been shown to interact with multiple other host proteins, including Mi2b, a component of the NURD histone deacetylase (Brehm et al., 1999) or the S4 subunit of the 26S proteasome (Berezutskaya and Bagchi, 1997) . However, it remains to be elucidated whether these interactions complement the growth promoting activity of HPV E7 or contribute to different functions necessary for the viral life cycle (reviewed in Munger et al., 2001) .
Unscheduled induction of cell growth induced by the E7 oncoprotein triggers an antiproliferative response in the host cell. One of the most powerful growth suppressive cellular defense mechanisms is triggered through activation of the p53 tumor suppressor (reviewed in Vogelstein et al., 2000) . The cooperating HPV E6 oncoprotein abrogates p53-mediated checkpoint response by interacting with and inducing accelerated proteasomal degradation of p53 (Scheffner et al., 1990; Werness et al., 1990) . This function of E6 involves its interaction with a host cell ubiquitin ligase, E6-AP (Huibregtse et al., 1991; Scheffner et al., 1993) , the founding member of the HECT domain E3 ubiquitin ligase family (Huibregtse et al., 1995) . Another function of HPV E6 that likely contributes . This results in uncontrolled E2F-mediated transcription of genes required for S phase entry as well as atypical cdk2 activation patterns. Unscheduled G1/S progression can trigger p53-dependent growth-suppressive pathways. To maintain a replication-competent milieu in the host cell, the cooperating HPV E6 oncoprotein stimulates the accelerated proteasomal degradation of p53, thereby relaxing p53-mediated checkpoint control. Cdk2, pRB, E2F, and p53 have each been implicated in centrosome homeostasis to the malignant phenotype is its ability to increase expression of telomerase (Klingelhutz et al., 1996) . Like E7, HPV E6 has also been reported to interact with a variety of additional host cellular proteins (reviewed in Howley and Lowy, 2001) . In summary, co-expression of HPV E6 and E7 results in sustained replication competence of differentiating host keratinocytes as a prerequisite for the productive viral life cycle. However efficient, this replication strategy harbors the danger of harming the host cell if the E6 and E7 oncoproteins are aberrantly expressed. Dysregulated expression of these viral oncoproteins can occur after integration of highrisk HPV DNA into a host chromosome. Viral genome integration is irreversible and terminates the viral life cycle. Importantly, viral integration associated with carcinogenic progression often leads to disruption of the E2 open reading frame which causes increased expression of the E6 and E7 oncoproteins. In more than 95% of cervical cancers, viral DNA is found integrated into the host cell genome and only E6 and E7 oncoprotein expression is regularly retained. Stable expression of HPV E6 and E7 oncoproteins is essential for the induction and maintenance of the transformed state (reviewed in Howley and Lowy, 2001) .
High-risk HPV E6 and E7 oncoproteins can immortalize normal epithelial cells (Hawley-Nelson et al., 1989; Munger et al., 1989) , however, malignant transformation is an infrequent event overall that can occur after long-term cultivation (Hurlin et al., 1991) . Similarly, malignant conversion of high-risk HPV positive lesions in patients can have a latency period of years to decades and develops only relatively rarely.
These findings demonstrate that high-risk HPVs initiate carcinogenesis but malignant progression critically depends on additional modifications of the host genome. Like in other cancer models, cellular mutations may arise in response to exposure to cocarcinogens. However, since high-risk HPVs can induce genomic instability (White et al., 1994) , prolonged exposure to HPV gene expression per se dramatically increases the risk that pro-carcinogenic genetic changes may accumulate.
Human papillomaviruses and genomic instability
Genomic instability is frequently observed in HPVassociated cervical cancer as well as in many other human malignancies (reviewed in Lengauer et al., 1998) . Loss of control over genome integrity can result in various progressive genetic abnormalities. In general, chromosomal instability can occur at different levels ranging from single mutations to gross chromosomal aberrations. The latter can be grouped into structural and numerical chromosomal changes. Structural changes include deletions or amplifications of chromosomal regions, but also translocations or, for example, the formation of ring or dicentric chromosomes. The pathogenesis of structural chromosome abnormalities usually involves chromosome breakage (reviewed in Gisselsson, 2001 ). Numerical chromosomal abnormalities, aneuploidy, are changes of the chromosome copy number in cells and represent one of the most frequent manifestations of chromosomal instability in solid human tumors. Under some conditions, cells with variable chromosome numbers are constantly generated giving rise to a considerable intratumor heterogeneity and aneuploidy. However, in many tumors, gains or losses of certain chromosomes as a result of an initial phase of high genomic instability can lead to the expansion of a clonal population that stably retains these changes over a long period of time. Regardless of whether abnormal chromosome numbers are continuously generated or stably maintained, numerical chromosome alterations are often caused by infidelity of chromosome segregation during mitosis (reviewed by Pihan and Doxsey, 1999) .
Chromosomal instability with gains and losses of whole chromosomes is a common finding in HPV immortalized cell lines (Hashida and Yasumoto, 1991; Solinas-Toldo et al., 1997) . HPV-associated clinical lesions are aneuploid already at early, noninvasive stages (Bulten et al., 1998; Jones et al., 1967; Reid et al., 1984; Rihet et al., 1996; Steinbeck, 1997) . The development of aneuploidy is clearly linked to the presence of high-risk HPV types and is absent in lesions caused by low-risk HPV infections (Fu et al., 1981) . There are indications that aneuploidy in HPVassociated cervical lesions may be preceded by an intermediate tetraploid stage (Southern et al., 1997 (Southern et al., , 2001 ). Aneuploid intraepithelial lesions have a higher risk for carcinogenic progression demonstrating the important role of chromosomal instability in cervical cancer (Bibbo et al., 1989; Kashyap and Das, 1998) .
Several lines of evidence suggest that the high-risk HPV E6 and E7 oncoproteins contribute directly to the development of genomic instability, however, the mechanisms are likely to be different. When selected for resistance against N-(phosphonoacetyl)-L-aspartate (PALA), normal human fibroblasts develop a distinct set of genetic abnormalities dependent on the viral oncoprotein they express. HPV-16 E6 expressing fibroblasts attain PALA resistance by amplification of the respective resistance locus. In contrast, fibroblasts expressing HPV-16 E7 develop PALA resistance by acquiring multiple copies of the chromosome that carries the resistance gene and become aneuploid (White et al., 1994) . It is interesting to note that certain selection conditions provoke specific forms of chromosomal changes (Bardelli et al., 2001) , however, these results are consistent with the model that expression of HPV-16 E7 reduces mitotic fidelity. Further support for this notion comes from the observation that rodent keratinocytes expressing the E7 oncoprotein showed a progressive loss of chromosomes with increased passage numbers whereas numerical imbalances were not detected in high-risk HPV E6 expressing cells (Hashida and Yasumoto, 1991) . Recent results show that one mechanism by which HPV-16 E7 can undermine the mitotic machinery is the induction of abnormal centrosome numbers.
HPV-16 E7 induces centrosome duplication errors
Abnormal multipolar mitoses are a morphological correlate for disturbances of mitotic fidelity. In cervical cancer, multipolar mitoses are abundant, and have long been recognized as a diagnostic feature of a highrisk HPV infection . It has been shown that these multipolar mitoses are associated with abnormal numbers of mitotic spindle poles that are formed by centrosomes (Duensing et al., 2000) . The incidence of cells with abnormal centrosome numbers increases in parallel with clinical progression during HPV-associated cervical carcinogenesis (Skyldberg et al., 2001) .
Centrosome abnormalities have been detected in virtually all major human malignancies including breast, colon and prostate cancer (Lingle et al., 1998; Pihan et al., 1998) . However, the mechanisms that contribute to the pathogenesis of numerical and/or structural centrosome abnormalities in these tumors have not been determined in detail. This may be because the nature and sequence of the underlying genetic changes in many malignant tumors is still largely unknown. HPV-associated cervical cancer offers a unique model because of its high association with high-risk HPV oncoproteins. Moreover, and as mentioned previously, expression of the E6 and E7 oncoproteins in normal human epithelial cells accurately recapitulates many aspects of cervical carcinogenesis in a simple tissue culture model. Hence, the role of distinct oncogenic stimuli for the induction of centrosome abnormalities and genomic instability can be studied, and several fundamental questions concerning centrosome duplication errors for the genesis of cancer have now been addressed using this experimental system. These include the contentious issue whether centrosome abnormalities can drive genomic instability or if they merely represent markers of genomically unstable cells, and the question how early during carcinogenic progression centrosomerelated mitotic disturbances occur.
The initial evidence that high-risk HPV E6 and E7 may be directly involved in the generation of abnormal centrosome numbers comes from experiments with primary human keratinocyte populations engineered to ectopically express these viral proteins. Cells stably expressing the E6 or E7 oncoprotein each contained abnormal centrosome numbers (Duensing et al., 2000) . Co-expression of HPV-16 E6 and E7 resulted in an even higher number of cells with supernumerary centrosomes suggesting a cooperative effect. Remarkably, cells expressing the low-risk HPV-6 E6 and E7 proteins did not contain abnormal centrosome numbers, consistent with the low potential for malignant progression of low-risk HPV-associated genital lesions (Duensing et al., 2000) . More insightful, however, were experiments in which HPV-16 E6 and E7 were expressed under transient conditions. Here, HPV-16 E7 was found to rapidly induce abnormal numbers of centrosomes within 48 h, i.e., within one or two population doublings. In contrast, the cooperating E6 oncoprotein had no significant effect on centrosome homeostasis under identical conditions (Duensing et al., 2000) .
There are several lines of evidence that the effect of HPV-16 E7 on centrosome homeostasis is caused by duplication errors and not simply by an accumulation of centrosomes (Figure 2 ). HPV-16 E7 was found to rapidly induce excessive numbers of centrioles, the core forming units of centrosomes (Figure 2a,b ) (Duensing et al., 2001a) . Moreover, there was an increase of procentrioles in E7 oncoprotein expressing cells as determined by electron microscopy ( Figure  2c,d) (Duensing et al., 2000) . Finally, there is evidence that HPV-16 E7 rapidly increases the proportion of functionally immature centrioles in cells while leaving the number of mature centrioles primarily unaffected (Duensing and Mu¨nger, unpublished observation) . Taken together, these findings suggest that HPV-16 E7 induces abnormal centrosome numbers by triggering aberrant duplication of centrioles, some of which eventually give rise to fully mature functional centrosomes that can cause multipolar mitoses. This model is supported by the observation that in HPV oncoprotein expressing keratinocyte populations, the increased number of cells with centrosome abnormalities is accompanied by a parallel expansion of the number of cells with multipolar mitoses (Duensing et al., 2000) .
The mechanism(s) by which the E7 oncoprotein induces centrosome duplication errors may be at least in part related to the ability to deregulate cell cycle control. Multiple studies have shown that cell cycle deregulation by HPV-16 E7 is associated with upregulation of cyclin E (Martin et al., 1998) and cyclin A (Schulze et al., 1998) , unscheduled activation of E2F-controlled gene transcription, and dysregulation of cdk2 activity (Zerfass et al., 1995) . E2F-dependent gene transcription and activation of cdk2/cyclin E as well as cdk2/cyclin A complexes have all been implicated in regulating centrosome duplication (Hinchcliffe et al., 1999; Lacey et al., 1999; Matsumoto et al., 1999; Meraldi et al., 1999) for example by phosphorylation of B23/nucleophosmin (Okuda et al., 2000) or activation of mMps1 kinase (Fisk and Winey, 2001) . Evidence that cell cycle dysregulation contributes importantly to E7 oncoprotein induced centrosome duplication errors is supported by the observation that a deletion mutant of HPV-16 E7 which lacks the conserved LXCXE pRB-binding domain is inactive with respect to the induction of abnormal centrosome numbers (Duensing et al., 2000) . Moreover, imposing a cell cycle block by using a dominant-negative mutant of DP1, a heterodimerization partner required for E2F transcriptional activity, or roscovitine, a pharmacological cdk inhibitor, also abrogated HPV-16 E7 induced abnormal centrosome duplication (Duensing et al., 2000) . These results do not rule out that the E7 oncoprotein also interferes with other known or unknown regulators of the centrosome duplication cycle, yet our present results suggest that the ability of HPV E7 to induce centrosome duplication errors is intimately linked to its ability to dysregulate the host cell cycle machinery.
HPV-16 E7 induced centrosome abnormalities can drive genomic instability
Theodor Boveri postulated more than 100 years ago that cancer cells may arise from a single multipolar cell division (Boveri, 1914) . There is an ongoing debate whether centrosome abnormalities cause genomic instability or whether they simply accumulate in tumor cells and thus are a mere reflection of genomic destabilization by other mechanisms. Recent studies have argued that cytokinesis defects not only result in increased ploidy and multinucleation but also cause the generation of polycentrosomal cells (Meraldi et al., 2002) . In such cells, supernumerary centrosomes accumulate in parallel with nuclear abnormalities and do not primarily originate from enhanced duplication. In many malignant tumors, cells with multiple nuclei as well as other nuclear abnormalities are readily detectable, suggesting that cytokinesis defects may contribute to a sizeable fraction of cells with centrosome abnormalities. However, even if the majority of multipolar mitoses are abortive events, it is important to determine whether centrosome abnormalities can occur in cells that are able to enter mitosis and divide into viable daughter cells.
Investigation of HPV oncoprotein-induced centrosome abnormalities clearly demonstrates that accumulation of centrosomes and primary centrosome duplication errors are not mutually exclusive, conceptually opposing models. On the contrary, both processes can exist in parallel and moreover there appears to be cooperation between the two mechanisms (reviewed in Duensing and Munger, 2001) . In order to drive genomic destabilization, centrosome duplication errors would have to develop in otherwise normal cells. HPV-16 E7 has been shown to induce abnormal centrosome numbers in primary human cells with normal nuclear morphology and normal numbers of certain marker chromosomes (Duensing et al., 2001a) . Although only an approximation, these three parameters, primary cell type, normal phenotype, and normal genotype, strongly suggest that the E7 oncoprotein induces a primary centrosome duplication defect thereby acting as a mitotic mutator. Notably, normal cells with centrosome duplication errors may be more likely to be capable of undergoing further cell divisions than cells with multiple nuclei or other manifestations of disturbed cytokinesis. In striking contrast to high-risk HPV E7, cells expressing the HPV-16 E6 oncoprotein develop abnormal centrosome numbers in parallel with multinucleation ( Figure 3) . In fact, we detected an excellent correlation between the degree of centrosome amplification and the degree of multinucleation in HPV-16 E6 expressing keratinocyte populations (Duensing et al., 2001a) . Staining for proliferation-associated markers revealed that some multinucleated HPV-16 E6 expressing cells continue to replicate DNA further supporting the idea that endoreduplication cycles contribute to abnormal centrosome duplication. Some of these multinucleated Figure 3 Accumulation of centrosomes in parallel with nuclear atypia and multinucleation in HPV-16 E6 oncoprotein expressing cells. In marked contrast to cells expressing the E7 oncoprotein, centrosome abnormalities in HPV-16 E6 expressing populations occur in cells that also show signs of nuclear atypia. This includes the formation of macronuclei, multinucleation, irregular shape of the nuclei, and chromatin connections between nuclei. In these cells, the number of abnormal centrosomes (arrowhead; insert) correlates with the degree of multinucleation. g-tubulin staining for centrosomes (red), nuclei counterstained with DAPI. Scale bar indicates 10 mm cells can eventually acquire a sensescence-like phenotype (Duensing et al., 2001a) .
It is important to emphasize that HPV E6 and E7 are co-expressed in cervical neoplasia and one would expect that both processes, primary centrosome duplication errors caused by E7, and accumulation of abnormal centrosome numbers in multinucleated cells caused by E6, occur simultaneously. Co-expression of E6 and E7 oncoproteins results in increased numbers of cells with numerical centrosome aberrations and multipolar mitoses relative to cells with expression of single HPV oncoproteins (Duensing et al., 2000) . Thus, even though in a given tumor most cells with centrosome abnormalities may also display multinucleation and nuclear atypia, there may be a small number of cells with centrosome abnormalities that are able to undergo mitosis and hence may constitute a primary and important source for mitotic infidelity. Although these may be rare and morphologically inconspicuous cells, we postulate that such cells increase the risk for genome destabilization and carcinogenic progression. Whereas it is possible that many oncogenic stimuli result in centrosome accumulation rather than in primary centrosome duplication errors, the HPV-16 E7 oncoprotein is a good candidate for an oncogenic stimulus that directly drives centrosome duplication errors and hence supports Boveri's original postulate that under some conditions centrosome abnormalities may drive genome destabilization and carcinogenic progression (Figure 4 ).
HPV oncoprotein-induced centrosome abnormalities in organotypical models of carcinogenesis
Three-dimensional organotypic tissue culture systems have been important contributors to our understanding of tumorigenesis (Muthuswamy et al., 2001) . Keratinocytes can be grown as 'raft' cultures where a stratified epithelium-like structure forms at the interface between culture media and air. Raft cultures of high-risk HPV expressing keratinocytes resemble highgrade cervical dysplasia (McCance et al., 1988) . Moreover, such raft culture systems also support episomal maintenance of HPV DNA (Dollard et al., 1992; Meyers et al., 1992) . In these rafts, the viral life cycle is recapitulated with HPV episomes maintained at a low copy number in the basal layer of the rafts and high-copy amplification in suprabasal cells. Similar to high-risk HPV-associated intraepithelial lesions in patients (Duensing et al., 2000; Skyldberg et al., 2001) , raft cultures expressing HPV episomes are aneuploid (Duensing et al., 2001b) . Investigation of centrosome abnormalities in organotypic keratinocyte cultures containing HPV episomes (Flores et al., 1999) revealed that numerical centrosome abnormalities are present already in basal cells containing HPV episomes at a low-copy number (Duensing et al., 2001b) . Interestingly, cells with HPV-16 epsiomes in which the E7 oncoprotein was inactivated showed a significant reduction of basal cells with centrosome abnormalities (Duensing et al., 2001b) . Multipolar mitoses were detected in suprabasal layers of the rafts. In support of the hypothesis that the E7 oncoprotein drives centrosome amplification, basal cells with abnormal centrosome numbers and low-copy episomes were found to be mononucleated (Duensing et al., 2001b) . These results suggest that expression of E6 and E7 from HPV-16 episomes is sufficient to induce centrosome duplication errors. This implies that viral integration and subsequent overexpression of HPV E6 and E7 is not required for the generation of centrosome abnormalities and confirm that centrosome abnormalities can occur early during HPV-associated carcinogenesis at a pre-invasive stage.
Centrosome duplication errors and virus propagation: sine qua non or side effect?
It is not known whether centrosome duplication errors and centrosome-related mitotic defects are beneficial for viral infection and replication. In malignant tumors, mitotic infidelity can be a selection advantage because it increases the chance that certain chromosomes which harbor tumor suppressor genes for example p53 on chromosome 17 are lost (reviewed in Cahill et al., 1999) . Such events may confer a growth advantage to certain subpopulations of tumor cells that, under specific conditions of hypoxia and other forms of cellular stress, undergo clonal expansion. Indeed, it has been proposed that 'the right amount' of chromosomal instability may be indispensable for tumor cells to overcome selection Figure 4 Centrosome duplication errors and centrosome accumulation in HPV oncoprotein expressing cells. Based on analyses of primary human cells expressing high-risk HPV-16 E6 or E7, the following model may be postulated. (a) HPV-16 E7 drives the generation of abnormal centrosome numbers by inducing a primary centrosome duplication defect. Since HPV E7 can induce abnormal centrosome numbers in cells that appear phenotypically normal, there is an increased likelihood that these cells will undergo further cell divisions and some may give rise to genomically unstable yet viable daughter cells. (b) In contrast, abnormal centrosome numbers in cells expressing the E6 oncoprotein accumulate together with other cellular defects as manifested by multinucleation and nuclear atypia. These cells are unlikely to be able to successfully complete a cell division but rather re-duplicate their DNA. Some of these multinucleated polycentrosomal cells withdraw from the proliferative pool and eventually acquire a senescence-like phenotype barriers during carcinogenic progression (reviewed in Cahill et al., 1999) . In HPV-immortalized cells, transfer of single chromosomes, for example chromosomes 2, 3, 4, 10 or 11, each resulted in a dramatically reduced cellular growth and ultimately replicative senescence (Baksch et al., 2001; Koi et al., 1989; Poignee et al., 2001; Uejima et al., 1995) . Therefore, loss of certain chromosomes may contribute to thwart the antiproliferative response of the host cell upon cell cycle re-programming by the E6 and E7 oncoproteins. Whether this mechanism contributes to the ability of high-risk HPVs to be maintained for many years in infected epithelia remains to be determined.
Genetic abnormalities accumulate during multistep carcinogenic progression, and it has been demonstrated that aneuploidy can develop in tissues before morphological signs of malignancy or even dysplasia are manifest (reviewed in Hittelman, 2001) . It is therefore plausible that the development of chromosomal instability can be a very early step during carcinogenic progression preceding morphological changes. The high-risk HPV-encoded oncoproteins may initiate genomic instability leading to chromosomal changes, which accumulate with persistence of the viral infection and eventually result in carcinogenic progression ( Figure  5 ) (Larson et al., 1997) . It has been postulated that HPVinduced genomic instability may drive integration of the viral genome (Kessis et al., 1996) . Additional steps of malignant progression may be further promoted by risk factors such as genetic predisposition of the host, immunosuppression, or exposure to chemical or environmental carcinogens. With centrosome-related mitotic defects representing only one contributing factor for the development of complex genetic changes, future studies will address the question what other mechanisms are involved in HPV-induced genome destabilization and how genomic instability in general can be exploited as a preventive or therapeutic target for antineoplastic treatment strategies. Figure 5 A model for HPV-associated cervical carcinogenesis. Infection with high-risk HPV types can lead to pre-invasive intraepithelial cervical lesions in which HPV DNA is maintained as episomes and virus production occurs in the suprabasal strata of the infected epithelium. Aneuploidy occurs already at this early stage and abnormal centrosome numbers as well as multipolar mitoses are present. Whereas the vast majority of these lesions ultimately regress, some lesions undergo malignant transformation which is frequently associated with integration of viral genome into host chromosomes. Following the integration event, the viral life cycle is irreversibly interrupted but expression of the E6 and E7 oncoproteins is retained and dysregulated. Transition from intraepithelial lesions to cancer is not only associated with enhanced centrosome abnormalities and aneuploidy, but also with other genetic changes, most prominently gains of chromosome arm 3q (see text for details)
